A joint scientific study conducted by researchers at the Institute of Medical Research in New Zealand, in cooperation with the Imperial London College, the University of Otago, the Starsp Children’s Hospital and the University of Auckland, revealed a new treatment for asthma in children, through a dual anti -inflammatory inhalation device that combines two medications at the same time; It reduces asthma in children in a large percentage compared to the current standard, without any additional side risks.
According to the experiments conducted by experts and included 360 children from all over New Zealand, they were randomly distributed to use either the dual inhalation or Salptamol when needed to relieve asthma symptoms, and the study lasted for a whole year, they found that the dual system does not cause differences in children’s growth or lung function or their control in asthma compared to the standard medicine, which confirms the safety of using it.
The results also showed that the inhalation device that combines the “podisonide” corticosteroid (Podisonide) and the rapidly effective bronchial expansion (formoterol), reduced the asthma seizures by 45% compared to the liptamol, currently used as a basic treatment, besides that the rate of seizures in children who used the double device was 0.23 cases per year per participant compared to 0.41 cases in a group Salptamol, which means that for every 100 children with light asthma, the number of asthma seizures can be reduced by 18 cases annually.
“This study is an important step to fill the cognitive gap between the methods of asthma treatment in adults and children, and for the first time we have proven that the double system significantly reduces asthma attacks in children with light asthma, which may improve the results of asthma treatment globally.”
The scientific results of the study concluded that asthma is one of the dangerous chronic diseases in children, and its tips may reach the threat of life, so reducing the repetition and severity of seizures is a vital medical goal, and therefore this study provides a strong guide to updating the instructions of asthma treatment for children globally, in line with the guidelines of adults, which may benefit millions of children around the world with light and medium asthma.